ANTX Stock Forecast 2025-2026
Distance to ANTX Price Targets
ANTX Price Momentum
10 Quality Stocks Worth Considering Now
Researching AN2 Therapeutics (ANTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ANTX and similar high-potential opportunities.
Latest ANTX Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, ANTX has a neutral consensus with a median price target of $2.00 (ranging from $1.00 to $5.00). The overall analyst rating is Hold (5.6/10). Currently trading at $1.40, the median forecast implies a 42.9% upside. This outlook is supported by 1 Buy, 3 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Roy Buchanan at Citizens Capital Markets, projecting a 257.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANTX Analyst Ratings
ANTX Price Target Range
Latest ANTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 25, 2025 | Citizens Capital Markets | Roy Buchanan | Market Outperform | Reiterates | $5.00 |
| Feb 3, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $5.00 |
| Nov 19, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $5.00 |
| Nov 18, 2024 | TD Cowen | Ritu Baral | Hold | Downgrade | $0.00 |
| Aug 9, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $3.00 |
| Jul 3, 2024 | Leerink Partners | Joseph Schwartz | Outperform | Upgrade | $0.00 |
| May 16, 2024 | Evercore ISI Group | Liisa Bayko | In-Line | Maintains | $2.00 |
| Apr 2, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Upgrade | $6.00 |
| Apr 1, 2024 | Oppenheimer | Jeff Jones | Perform | Reiterates | $0.00 |
| Feb 13, 2024 | Leerink Partners | Joseph Schwartz | Market Perform | Downgrade | $7.00 |
| Feb 12, 2024 | Evercore ISI Group | Liisa Bayko | In-Line | Downgrade | $7.00 |
| Feb 12, 2024 | Oppenheimer | Jeff Jones | Perform | Downgrade | $0.00 |
| Feb 12, 2024 | JMP Securities | Roy Buchanan | Market Perform | Downgrade | $0.00 |
| Jan 4, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Initiates | $30.00 |
| Mar 30, 2023 | Oppenheimer | Jeff Jones | Outperform | Maintains | $24.00 |
| Nov 14, 2022 | SVB Leerink | Joseph Schwartz | Outperform | Maintains | $25.00 |
| Apr 19, 2022 | Evercore ISI Group | Liisa Bayko | Outperform | Initiates | $25.00 |
| Apr 19, 2022 | Oppenheimer | Kevin DeGeeter | Outperform | Initiates | $22.00 |
| Apr 19, 2022 | Cowen & Co. | Ritu Baral | Outperform | Initiates | $0.00 |
An2 Therapeutics Inc. (ANTX) Competitors
The following stocks are similar to AN2 Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
An2 Therapeutics Inc. (ANTX) Financial Data
An2 Therapeutics Inc. has a market capitalization of $41.83M with a P/E ratio of -0.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -53.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
An2 Therapeutics Inc. (ANTX) Business Model
About An2 Therapeutics Inc.
Develops therapies for infectious diseases.
An2 Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, focusing on developing innovative therapies to address unmet medical needs in infectious diseases. The company primarily generates revenue through the commercialization of its drug candidates, particularly targeting NTM lung disease, an area with significant treatment gaps.
An2 Therapeutics is strategically positioned to tackle drug-resistant infections, a growing global health issue. The company employs advanced research and development strategies to create new medicines, aiming to bring life-saving therapeutics to market. This focus on critical healthcare solutions enhances its potential appeal to investors interested in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
41
CEO
Mr. Eric E. Easom
Country
United States
IPO Year
2022
Website
www.an2therapeutics.comAn2 Therapeutics Inc. (ANTX) Latest News & Analysis
AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced that CEO Eric Easom will present at the Leerink Partners Global Healthcare Conference.
AN2 Therapeutics' presentation at a key healthcare conference highlights its leadership and potential innovations, which can influence investor confidence and stock performance.
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
20 days agoAN2 Therapeutics (Nasdaq: ANTX) submitted an amended statistical analysis plan to the FDA, designating the QOL-B respiratory domain as the primary efficacy endpoint for its Phase 3 EBO-301 trial.
AN2 Therapeutics' FDA submission for a key trial endpoint signals progress in developing its therapies, potentially impacting stock value and market confidence in the company's prospects.
AN2 Therapeutics, Inc. (Nasdaq: ANTX) will participate in two investor conferences in March, including the TD Cowen Health Care Conference, where CEO Eric Easom will present a corporate overview.
AN2 Therapeutics' participation in investor conferences signals potential growth opportunities and increased visibility, which can influence stock performance and investor sentiment.
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
1 month agoAN2 Therapeutics, Inc. (Nasdaq: ANTX) announced CEO Eric Easom will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference.
AN2 Therapeutics' participation in a prominent healthcare conference raises visibility and credibility, potentially attracting investor interest and impacting stock performance.
AN2 Therapeutics, Inc. reported Q3 2024 financial results and updated on the Phase 2 EBO-301 trial for refractory MAC lung disease, highlighting limited treatment options.
AN2 Therapeutics' Phase 2 trial update signals potential advancements in treating refractory MAC lung disease, which could impact drug development timelines and market valuation.
AN2 Therapeutics (Nasdaq: ANTX) secured a second-year research grant from the Bill & Melinda Gates Foundation to develop novel boron-based therapeutics for tuberculosis and malaria.
AN2 Therapeutics' continued funding from the Gates Foundation signals confidence in its research, potentially enhancing its market position and attracting further investment.
Frequently Asked Questions About ANTX Stock
What is An2 Therapeutics Inc.'s (ANTX) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, An2 Therapeutics Inc. (ANTX) has a median price target of $2.00. The highest price target is $5.00 and the lowest is $1.00.
Is ANTX stock a good investment in 2025?
According to current analyst ratings, ANTX has 1 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $1.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANTX stock?
Wall Street analysts predict ANTX stock could reach $2.00 in the next 12 months. This represents a 42.9% increase from the current price of $1.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is An2 Therapeutics Inc.'s business model?
An2 Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, focusing on developing innovative therapies to address unmet medical needs in infectious diseases. The company primarily generates revenue through the commercialization of its drug candidates, particularly targeting NTM lung disease, an area with significant treatment gaps.
What is the highest forecasted price for ANTX An2 Therapeutics Inc.?
The highest price target for ANTX is $5.00 from Roy Buchanan at Citizens Capital Markets, which represents a 257.1% increase from the current price of $1.40.
What is the lowest forecasted price for ANTX An2 Therapeutics Inc.?
The lowest price target for ANTX is $1.00 from at , which represents a -28.6% decrease from the current price of $1.40.
What is the overall ANTX consensus from analysts for An2 Therapeutics Inc.?
The overall analyst consensus for ANTX is neutral. Out of 6 Wall Street analysts, 1 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $2.00.
How accurate are ANTX stock price projections?
Stock price projections, including those for An2 Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
